New Triple-Threat attack on tough lung cancer aims to enable surgery
NCT ID NCT07131319
Summary
This study is testing a three-part treatment for stage III non-small cell lung cancer that cannot initially be removed by surgery. The goal is to see if combining a specialized form of radiation (SFRT) with an immunotherapy drug (tislelizumab) and standard chemotherapy can shrink tumors enough so that surgery becomes an option. Researchers will measure how many patients can have surgery after this treatment and monitor the safety of the combination.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanchang City, Jiangxi Province
RECRUITINGNanchang, Jiangxi, 330000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.